February 7, 2025 - 02:25

Viking Therapeutics has provided an update on its financial performance for the fourth quarter of 2024 while highlighting the progress of its oral VK2735 in Phase 2 clinical trials. The company reported significant advancements in its research and development efforts, particularly focusing on VK2735, a novel therapeutic candidate aimed at addressing metabolic disorders.
The Phase 2 trials are crucial for determining the efficacy and safety of VK2735, with results anticipated in the second half of 2025. This timeline positions Viking Therapeutics to potentially make substantial contributions to the treatment landscape for conditions such as obesity and type 2 diabetes. The company is optimistic about the ongoing trials and remains committed to delivering innovative solutions for patients.
In addition to the clinical advancements, Viking's financial results reflect a strategic approach to funding its research initiatives. The company continues to explore opportunities for growth and collaboration in the biotechnology sector, ensuring that it remains at the forefront of medical innovation.
November 19, 2026 - 02:04
MVB Financial Corp Announces Fourth Quarter DividendFAIRMONT, W.Va., November 18, 2026--MVB Financial Corp has declared a quarterly cash dividend of $0.17 per share, maintaining the same rate as the previous quarter. This decision reflects the...
November 18, 2026 - 11:00
How States Can Use Progressive Tax Policies to Expand Financial AidAs states face increasing pressure to make higher education more affordable, progressive taxation strategies are emerging as a viable solution. By implementing tax policies that place a greater...
November 17, 2026 - 23:07
Financial Struggles Plague Over Half of Households in HawaiiRecent reports reveal that a significant number of households in Hawaii are facing severe financial difficulties, leading to widespread stress and anxiety. Many residents are struggling to sleep...
November 17, 2026 - 06:46
Two Years After COP29, Companies Face Financial Impact from Carbon PricingAs businesses navigate the aftermath of COP29, the financial landscape is shifting under the weight of rising carbon prices and new regulations like the Carbon Border Adjustment Mechanism (CBAM)....